Through bioinformatic analysis, molecular simulation, and cell-level experiments, seven approved drugs were identified as potential NUDT5 inhibitors and were proved to have a cytotoxic effect on estrogen-receptor-positive breast cancer cell line MCF7 [71]. This evidence concerns the gene NUDT5 and breast carcinoma.